Skip to main content

Advertisement

SpringerLink
Log in

Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Skin and soft tissue infections (SSTIs) are common illnesses that have a significant impact on health care management. Community-associated, methicillin-resistant Staphylococcus aureus (CA-MRSA) infections have been documented among healthy individuals without predisposing risk factors. The appearance and spread of CA-MRSA represent a new challenge in pediatric medicine and have important clinical implications for therapy of infections caused by S. aureus. This article provides a review of recent changes in the epidemiology of CA-MRSA, pathogenic potential, and therapeutic considerations in the management of SSTIs in children.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Miller LG, Perdreau-Remington F, Rieg G, et al.: Necrotizing fasciitis caused by community-associated methicillinresistant Staphylococcus aureus in Los Angeles. N Engl J Med 2005, 352:1445–1453. A report of 14 cases of CA-MRSA necrotizing fasciitis, an uncommon type of staphylococcal infection.

    Article  PubMed  CAS  Google Scholar 

  2. Saravolatz LD, Markowitz N, Arking L, et al.: Methicillinresistant Staphylococcus aureus. Epidemiologic observations during a community-acquired outbreak. Ann Intern Med 1982, 96:11–16.

    PubMed  CAS  Google Scholar 

  3. Levine DP, Cushing RD, Jui J, Brown WJ: Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982, 97:330–338.

    PubMed  CAS  Google Scholar 

  4. Herold BC, Immergluck LC, Maranan MC, et al.: Communityacquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA 1998, 279:593–598.

    Article  PubMed  CAS  Google Scholar 

  5. Fergie JE, Purcell K: Community-acquired methicillinresistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001, 20:860–863.

    Article  PubMed  CAS  Google Scholar 

  6. Gorak EJ, Yamada SM, Brown JD: Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999, 29:797–800.

    PubMed  CAS  Google Scholar 

  7. Groom AV, Wolsey DH, Naimi TS, et al.: Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001, 286:1201–1205.

    Article  PubMed  CAS  Google Scholar 

  8. Naimi TS, LeDell KH, Boxrud DJ, et al.: Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996–1998. Clin Infect Dis 2001, 33:990–996.

    Article  PubMed  CAS  Google Scholar 

  9. Naimi TS, LeDell KH, Como-Sabetti K, et al.: Comparison of community-and health care-associated methicillinresistant Staphylococcus aureus infection. JAMA 2003, 290:2976–2984.

    Article  PubMed  CAS  Google Scholar 

  10. Fey PD, Said-Salim B, Rupp ME, et al.: Comparative molecular analysis of community- or hospital-acquired methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47:196–203.

    Article  PubMed  CAS  Google Scholar 

  11. Daum RS, Ito T, Hiramatsu K, et al.: A novel methicillinresistance cassette in community-acquired methicillinresistant Staphylococcus aureus isolates of diverse genetic backgrounds. J Infect Dis 2002, 186:1344–1347. The authors show that type IV SCCmec is present in 11 of 12 CA-MRSA isolates with diverse genetic backgrounds as shown by different pulsotypes, ribotypes and coagulase serotypes.

    Article  PubMed  CAS  Google Scholar 

  12. Crawford SE, Daum RS: Epidemic community-associated methicillin-resistant Staphylococcus aureus: modern times for an ancient pathogen. Pediatr Infect Dis 2005, 24:459–460. A recent concise review that describes the molecular characteristic of CA-MRSA isolates.

    Article  Google Scholar 

  13. Ito T, Katayama Y, Asada K, et al.: Structural comparison of the three types of staphylococcal cassette chromosome mec in the chromosome of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2001, 45:1323–1336.

    Article  PubMed  CAS  Google Scholar 

  14. Ito T, Ma XX, Takeuchi F, et al.: Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004, 48:2637–2651. The authors describe the identification and genetic characterization of the novel type V SCCmec found in CA-MRSA isolate.

    Article  PubMed  CAS  Google Scholar 

  15. Centers for Disease Control and Prevention: Outbreaks of community-associated methicillin-resistant Staphylococcus aureus skin infections. http:/www.cdc.gov/mmwr/preview/ mmwrhtm/mm5205a4. htm.

  16. Purcell K, Fergie J: Epidemic of community-acquired MRSA infections: a 13-year study at Driscoll Children’s Hospital. Paper presented at the Annual Meeting of the Infectious Diseases Society of America [abstract 484]. Boston, MA; September 30-October 3, 2004.

  17. Baba T, Takeuchi F, Kuroda M, et al.: Genome and virulence determinants of high-virulence community-acquired MRSA. Lancet 2002, 359:1819–1827. The complete genome sequence of MW2, a CA-MRSA isolate, which caused fatal septicemia and septic arthritis in a 16-month-old girl without risk factors associated with healthcare was described.

    Article  PubMed  CAS  Google Scholar 

  18. LadhaniS: Recent developments in staphylococcal scalded skin syndrome. Clin Microbiol Infect 2001, 7:301–307.

    Article  PubMed  CAS  Google Scholar 

  19. Dinges MM, Orwin PM, Schlievert PM: Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000, 13:16–34.

    PubMed  CAS  Google Scholar 

  20. Lina G, Piemont Y, Godail-Gamot F, et al.: Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis 1999, 29:1128–1132.

    Article  PubMed  CAS  Google Scholar 

  21. Supersac G, Prevost G, Piemont Y: Sequencing of leucocidin R from Staphylococcus aureus P83 suggests that staphylococcal leucocidins and gamma-hemolysin are members of a single, two-component family of toxins. Infect Immun 1993, 61:580–587.

    PubMed  CAS  Google Scholar 

  22. Konig B, Prevost G, Piemont Y, Konig W: Effects of Staphylococcus aureus leukocidins on inflammatory mediator release from human granulocytes. J Infect Dis 1995, 171:607–613.

    PubMed  CAS  Google Scholar 

  23. Prevost G, Couppie P, Prevost P, et al.: Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 1995, 42:237–245.

    Article  PubMed  CAS  Google Scholar 

  24. Gillet Y, Issartel B, Vanhems P, et al.: Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 2002, 359:753–759.

    Article  PubMed  CAS  Google Scholar 

  25. Vandenesch F, Naimi T, Enright MC, et al.: Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978–984.

    PubMed  Google Scholar 

  26. Baggett HC, Hennessy TW, Rudolph K, et al.: Community-onset methicillin-resistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis 2004, 189:1565–1573. One of a number of recent reports about CA-MRSA skin and soft tissue infections and the association between those isolates and Panton-Valentine leukocidin.

    Article  PubMed  Google Scholar 

  27. Mongkolrattanothai K, Boyle S, Kahana MD, Daum RS: Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillinresistant isolates. Clin Infect Dis 2003, 37:1050–1058.

    Article  PubMed  Google Scholar 

  28. Martinez-Aguilar G, Avalos-Mishann A, Hulten K, et al.: Community-acquired methicillin-resistant and methicillinsusceptible Staphylococcus aureus musculoskeletal infection in children. Pediatr Infect Dis J 2004, 23:701–706.

    Article  PubMed  Google Scholar 

  29. Lee MC, Rios AM, Aten MF, et al.: Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004, 23:123–127.

    Article  PubMed  Google Scholar 

  30. Martinez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL: Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillinsusceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003, 22:593–598.

    Article  PubMed  Google Scholar 

  31. Kaplan SL, Hulten KG, Gonzalez BE, et al.: Three-year surveillance of community-acquired Staphylococcus aureus infections in children. Clin Infect Dis 2005, 40:1785–1791. A recent study of CA-MRSA infections at Texas Children’s Hospital that showed an alarming increase in the number of infections and hospitalizations caused by CA-MRSA isolates.

    Article  PubMed  Google Scholar 

  32. LeclercqR: Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002, 34:482–492. This paper provides an extensive and complete review about the mechanism of resistance to macrolides and lincosamides which is important reading to understand the complexicity in the therapy caused by S. aureus.

    Article  PubMed  CAS  Google Scholar 

  33. Siberry GK, Tekle T, Carroll K, Dick J: Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257–1260.

    Article  PubMed  Google Scholar 

  34. Sattler CA, Mason EO Jr, Kaplan SL: Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002, 21:910–917.

    Article  PubMed  Google Scholar 

  35. Clinical Laboratory Standards Institute (CLSI/ NCCLS):Approved Standards. 15th informational supplement. Wayne: CLSI/NCCLS; 2004.

  36. Baker CJ, Frenck RW: Guidelines for management of skin and soft tissue infections. AAP news 2004, 25:110–117.

    Google Scholar 

  37. Iyer S, Jones DH: Community-acquired methicillin-resistant Staphylococcus aureus skin infection: a retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004, 50:854–858.

    Article  PubMed  Google Scholar 

  38. Markowitz N, Quinn EL, Saravolatz LD: Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992, 117:390–398.

    PubMed  CAS  Google Scholar 

  39. Masters PA, O’Bryan TA, Zurlo J, et al.: Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003, 163:402–410.

    Article  PubMed  CAS  Google Scholar 

  40. Standiford HC: Tetracycline and chloramphenicol. Principles and Practice of Infectious Diseases. Edited by Mandell GL, Bennett JE, Dolin R. New York: Churchill Livingstone; 2000:336–348.

    Google Scholar 

  41. Ruhe JJ, Monson T, Bradsher RW, Menon A: Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis 2005, 40:1429–1434.

    Article  PubMed  CAS  Google Scholar 

  42. Barna JC, Williams DH: The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 1984, 38:339–357.

    Article  PubMed  CAS  Google Scholar 

  43. Fridkin SK, Hageman J, McDougal LK, et al.: Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997–2001. Clin Infect Dis 2003, 36:429–439.

    Article  PubMed  Google Scholar 

  44. Centers for Disease Control:Staphylococcus aureus resistant to vancomycin—United States 2002. MMWR Morb Mortal Wkly Rep 2002, 51:565–567.

    Google Scholar 

  45. Ford CW, Zurenko GE, Barbachyn MR: The discovery of linezolid, the first oxazolidinone antibacterial agents. Curr Drug Targets Infect Disord 2001, 1:181–199.

    Article  PubMed  CAS  Google Scholar 

  46. Kaplan SL, Deville JG, Yogev R, et al.: Linezolid Pediatric Study Group. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003, 22:677–686.

    PubMed  Google Scholar 

  47. Deville JG, Adler S, Azimi PH, et al.: Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003, 22(Suppl 9):S158-S163.

    PubMed  Google Scholar 

  48. Yogev R, Patterson LE, Kaplan SL, et al.: Linezolid for the treatment of complicated skin and skin structure infections in children. Pediatr Infect Dis J 2003, 22(Suppl 9):S172-S177.

    PubMed  Google Scholar 

  49. Jungbluth GL, Welshman IR, Hopkins NK: Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003, 22(Suppl 9):S153-S157.

    PubMed  Google Scholar 

  50. Wigen CL, Goetz MB: Serotonin syndrome and linezolid. Clin Infect Dis 2002, 34:1651–1652.

    Article  PubMed  Google Scholar 

  51. Pankey GA, Sabath LD: Clinical relevance of bacteriostatic versus bactericidal mechanism of action in the treatment of gram positive bacterial infection. Clin Infec Dis 2004, 38:864–870.

    Article  CAS  Google Scholar 

  52. Ruiz ME, Guerrero IC, Tuazon CU: Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002, 35:1018–1020.

    Article  PubMed  Google Scholar 

  53. French G: Safety and tolerability of linezolid. J Antimicrob Chemother 2003, 51(Suppl 2):ii45-ii53.

    PubMed  CAS  Google Scholar 

  54. Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther 2001, 23:24–44.

    Article  PubMed  CAS  Google Scholar 

  55. Nichols RL, Graham DR, Barriere SL, et al.: Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999, 44:263–273.

    Article  PubMed  CAS  Google Scholar 

  56. Rubinstein E, Prokocimer P, Talbot GH: Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999, 44(Suppl A):37–46.

    Article  PubMed  CAS  Google Scholar 

  57. Olsen KM, Rebuck JA, Rupp ME: Arthralgias and myalgias related to quinupritin-dalfopristin administration. Clin Infect Dis 2001, 32:e83–86.

    Article  PubMed  CAS  Google Scholar 

  58. Lakey JH, Ptak M: Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY146032 and phopholipid membranes. Biochemistry 1988, 27:4639–4645.

    Article  PubMed  CAS  Google Scholar 

  59. Critchley IA, Blosser-Middleton RS, Jones ME, et al.: In vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000–2001. Antimicrob Agents Chemother 2003, 47:1689–1693.

    Article  PubMed  CAS  Google Scholar 

  60. Tally FP, De Bruin MF: Development of daptomycin for grampositive infections. J Antimicrob Chemother 2000, 46:523–526.

    Article  PubMed  CAS  Google Scholar 

  61. Arbeit RD, Maki D, Tally FP, et al.: Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004, 38:1673–1681.

    Article  PubMed  CAS  Google Scholar 

  62. Silverman JA, Mortin LI, VanPraagh AD, et al.: Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis 2005, 191:2149–2152.

    Article  PubMed  CAS  Google Scholar 

  63. Cubicin (daptomycin for injection) [package insert]. Lexington, MA: Cubist Pharmaceuticals; 2003.

  64. Oleson FB Jr, Berman CL, Kirkpatrick JB, et al.: Once daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000, 44:2948–2953.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Chicago, 5841 South Maryland Avenue, MC 6054, 60637, Chicago, IL, USA

    Robert S. Daum MD

Authors
  1. Kanokporn Mongkolrattanothai MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert S. Daum MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mongkolrattanothai, K., Daum, R.S. Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children. Curr Infect Dis Rep 7, 381–389 (2005). https://doi.org/10.1007/s11908-005-0013-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-005-0013-1

Keywords

Search

Navigation